Journal article
Patient perceptions and use of non-statin lipid lowering therapy among patients with or at risk for atherosclerotic cardiovascular disease: Insights from the PALM registry
Clinical cardiology (Mahwah, N.J.), Vol.44(6), pp.863-870
06/01/2021
DOI: 10.1002/clc.23625
PMCID: PMC8207979
PMID: 34008247
Abstract
Background Non-statin lipid lowering therapies (LLTs) provide additional treatment options for patients. Use patterns and patient perceptions of non-statin LLT remain incompletely described.
Hypothesis The guideline-recommended statin intensity remains underutilized in patients treated with and without non-statin LLT.
Methods The PALM Registry collected LLT information on patients with or at risk of ASCVD treated at 125 US clinics in 2015. We compared patient perceptions, lipid levels and statin use among patients treated with and without non-statin LLT.
Results Among 7720 patients, 1930 (25.0%) were treated with a non-statin LLT (1249 fish oil, 417 fibrates, 329 ezetimibe, 196 niacin). Concurrent statin treatment occurred in 73.7%, of which 45.4% were dosed under the guideline-recommended intensity. Compared with patients on statin alone, patients receiving both a statin and non-statin LLT (n = 1423) were more likely to be male, white race and to perceive themselves as higher risk of ASCVD compared with their peers (38.5% vs. 34.9%, p = .047). Only 27.4% of patients treated with non-statin LLT alone perceived themselves at higher risk. Most (75.7%) patients treated with a non-statin LLT alone reported never being treated with a statin, despite ASCVD in 30.8% of these patients. Among those previously treated with a statin, 59.3% reported being willing to try a statin again.
Conclusions Non-statin LLT is used in one in four patients with or at risk for ASCVD; its use is frequently in place of statin therapy or in the absence of guideline-recommended statin intensity. More work is needed to establish statins as first line therapy.
Details
- Title: Subtitle
- Patient perceptions and use of non-statin lipid lowering therapy among patients with or at risk for atherosclerotic cardiovascular disease: Insights from the PALM registry
- Creators
- Angela Lowenstern - Duke UniversityShuang Li - Duke UniversityAnn Marie Navar - Duke UniversitySalim S. Virani - Baylor College of MedicineVeronique L. Roger - Mayo ClinicJennifer G. Robinson - University of IowaAnne C. Goldberg - Washington University in St. LouisWendy Kampman - RegeneronEric D. Peterson - Duke UniversityTracy Y. Wang - Duke University
- Resource Type
- Journal article
- Publication Details
- Clinical cardiology (Mahwah, N.J.), Vol.44(6), pp.863-870
- Publisher
- Wiley
- DOI
- 10.1002/clc.23625
- PMID
- 34008247
- PMCID
- PMC8207979
- ISSN
- 0160-9289
- eISSN
- 1932-8737
- Number of pages
- 8
- Grant note
- Regeneron Pharmaceuticals; Regeneron Sanofi
- Language
- English
- Date published
- 06/01/2021
- Academic Unit
- Epidemiology; Fraternal Order of Eagles Diabetes Research Center
- Record Identifier
- 9984363581802771
Metrics
6 Record Views